{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T00:01:04Z","timestamp":1787702464533,"version":"build-2784847793"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","funder":[{"name":"Eli Lilly and Company and Incyte Corporation"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1186\/s13075-017-1410-1","type":"journal-article","created":{"date-parts":[[2017,9,18]],"date-time":"2017-09-18T11:48:42Z","timestamp":1505735322000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":59,"title":["Patient-reported outcomes of baricitinib in patients with rheumatoid arthritis and no or limited prior disease-modifying antirheumatic drug treatment"],"prefix":"10.1186","volume":"19","author":[{"given":"Michael","family":"Schiff","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsutomu","family":"Takeuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roy","family":"Fleischmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol L.","family":"Gaich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy M.","family":"DeLozier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas","family":"Schlichting","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Ling","family":"Kuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji-Eon","family":"Won","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tara","family":"Carmack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terence","family":"Rooney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Durez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saeed","family":"Shaikh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodolfo Pardo","family":"Hidalgo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald","family":"van Vollenhoven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristiano A. F.","family":"Zerbini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,9,18]]},"reference":[{"key":"1410_CR1","doi-asserted-by":"publisher","unstructured":"Fleischmann R, Schiff M, van der Heijde D, Ramos-Remus C, Spindler A, Stanislav M, Zerbini CAF, Gurbuz S, Dickson C, de Bono S, et al. Baricitinib, methotrexate, or combination in patients with rheumatoid arthritis and no or limited prior disease-modifying antirheumatic drug treatment. Arthritis Rheumatol. 2017;69:506\u201317. doi: 10.1002\/art.39953 .","DOI":"10.1002\/art.39953"},{"key":"1410_CR2","first-page":"S14","volume":"23","author":"B Bruce","year":"2005","unstructured":"Bruce B, Fries JF. The Health Assessment Questionnaire (HAQ). Clin Exp Rheumatol. 2005;23:S14\u20138.","journal-title":"Clin Exp Rheumatol"},{"key":"1410_CR3","first-page":"227","volume-title":"Quality of life and pharmacoeconomics in clinical trials","author":"D Ramey","year":"1996","unstructured":"Ramey D, Fries J, Singh G. The Health Assessment Questionnaire 1995 \u2014 status and review. In: Spilker B, editor. Quality of life and pharmacoeconomics in clinical trials. 2nd ed. Philadelphia: Lippincott-Raven; 1996. p. 227\u201337.","edition":"2"},{"key":"1410_CR4","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1002\/art.1780360601","volume":"36","author":"DT Felson","year":"1993","unstructured":"Felson DT, Anderson JJ, Boers M, Bombardier C, Chernoff M, Fried B, et al. The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. The Committee on Outcome Measures in Rheumatoid Arthritis Clinical Trials. Arthritis Rheum. 1993;36:729\u201340.","journal-title":"Arthritis Rheum"},{"key":"1410_CR5","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.3899\/jrheum.090360","volume":"36","author":"JR Kirwan","year":"2009","unstructured":"Kirwan JR, Newman S, Tugwell PS, Wells GA, Hewlett S, Idzera L, et al. Progress on incorporating the patient perspective in outcome assessment in rheumatology and the emergence of life impact measures at OMERACT 9. J Rheumatol. 2009;36:2071\u20136.","journal-title":"J Rheumatol"},{"key":"1410_CR6","first-page":"1","volume":"68","author":"JA Singh","year":"2016","unstructured":"Singh JA, Saag KG, Bridges Jr SL, Akl EA, Bannuru RR, Sullivan MC, et al. 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Rheumatol. 2016;68:1\u201326.","journal-title":"Arthritis Rheumatol"},{"key":"1410_CR7","unstructured":"Smolen JS and Landew\u00e9 R. EULAR recommendations for the management of rheumatoid arthritis-2016 Update. EULAR Web site. Available at: http:\/\/www.eular.org\/myUploadData\/files\/EULAR%20RA%20Management%20recommendations%202016%20update%20June%202016-c_2.pdf . Accessed 01 Dec 2016."},{"key":"1410_CR8","unstructured":"Food and Drug Administration. Guidance for industry: rheumatoid arthritis: developing drug products for treatment: draft guidance. May 2013. Available at http:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/UCM354468.pdf . Accessed 20 June 2017."},{"key":"1410_CR9","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/annrheumdis-2015-207524","volume":"75","author":"JS Smolen","year":"2016","unstructured":"Smolen JS, Breedveld FC, Burmester GR, Bykerk V, Dougados M, Emery P, et al. Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. Ann Rheum Dis. 2016;75:3\u201315.","journal-title":"Ann Rheum Dis"},{"key":"1410_CR10","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/art.21519","volume":"54","author":"FC Breedveld","year":"2006","unstructured":"Breedveld FC, Weisman MH, Kavanaugh AF, Cohen SB, Pavelka K, van Vollenhoven R, et al. The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum. 2006;54:26\u201337.","journal-title":"Arthritis Rheum"},{"key":"1410_CR11","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1056\/NEJMoa1310476","volume":"370","author":"EB Lee","year":"2014","unstructured":"Lee EB, Fleischmann R, Hall S, Wilkinson B, Bradley JD, Gruben D, et al. Tofacitinib versus methotrexate in rheumatoid arthritis. N Engl J Med. 2014;370:2377\u201386.","journal-title":"N Engl J Med"},{"key":"1410_CR12","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1136\/ard.2008.105197","volume":"69","author":"G Jones","year":"2010","unstructured":"Jones G, Sebba A, Gu J, Lowenstein MB, Calvo A, Gomez-Reino JJ, et al. Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study. Ann Rheum Dis. 2010;69:88\u201396.","journal-title":"Ann Rheum Dis"},{"key":"1410_CR13","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S0140-6736(08)61000-4","volume":"372","author":"P Emery","year":"2008","unstructured":"Emery P, Breedveld FC, Hall S, Durez P, Chang DJ, Robertson D, et al. Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial. Lancet. 2008;372:375\u201382.","journal-title":"Lancet"},{"key":"1410_CR14","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1111\/1756-185X.12183","volume":"16","author":"P Nash","year":"2013","unstructured":"Nash P, Nicholls D. Perceptions of methotrexate use in rheumatoid arthritis by rheumatologists and their patients: an Australian survey study. Int J Rheum Dis. 2013;16:652\u201361.","journal-title":"Int J Rheum Dis"},{"key":"1410_CR15","unstructured":"RHEUMATREX\u00ae (methotrexate) [package insert]. Fort Lee: DAVA Pharmaceuticals, Inc; 2013. https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=2cb70aa1-f73a-41c8-9a7f-edbcf1a06efd . Accessed 5 Sept 2017."},{"key":"1410_CR16","first-page":"557","volume":"20","author":"GA Wells","year":"1993","unstructured":"Wells GA, Tugwell P, Kraag GR, Baker PR, Groh J, Redelmeier DA. Minimum important difference between patients with rheumatoid arthritis: the patient's perspective. J Rheumatol. 1993;20:557\u201360.","journal-title":"J Rheumatol"},{"key":"1410_CR17","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1002\/art.20048","volume":"50","author":"E Krishnan","year":"2004","unstructured":"Krishnan E, Sokka T, Hakkinen A, Hubert H, Hannonen P. Normative values for the Health Assessment Questionnaire disability index: benchmarking disability in the general population. Arthritis Rheum. 2004;50:953\u201360.","journal-title":"Arthritis Rheum"},{"key":"1410_CR18","first-page":"811","volume":"32","author":"D Cella","year":"2005","unstructured":"Cella D, Yount S, Sorensen M, Chartash E, Sengupta N, Grober J. Validation of the Functional Assessment of Chronic Illness Therapy Fatigue Scale relative to other instrumentation in patients with rheumatoid arthritis. J Rheumatol. 2005;32:811\u20139.","journal-title":"J Rheumatol"},{"key":"1410_CR19","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1002\/acr.22453","volume":"67","author":"V Strand","year":"2015","unstructured":"Strand V, Burmester GR, Zerbini CA, Mebus CA, Zwillich SH, Gruben D, et al. Tofacitinib with methotrexate in third-line treatment of patients with active rheumatoid arthritis: patient-reported outcomes from a phase III trial. Arthritis Care Res (Hoboken). 2015;67:475\u201383.","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"1410_CR20","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1002\/art.23715","volume":"59","author":"E Keystone","year":"2008","unstructured":"Keystone E, Burmester GR, Furie R, Loveless JE, Emery P, Kremer J, et al. Improvement in patient-reported outcomes in a rituximab trial in patients with severe rheumatoid arthritis refractory to anti-tumor necrosis factor therapy. Arthritis Rheum. 2008;59:785\u201393.","journal-title":"Arthritis Rheum"},{"key":"1410_CR21","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1136\/bmj.305.6846.160","volume":"305","author":"JE Brazier","year":"1992","unstructured":"Brazier JE, Harper R, Jones NM, O'Cathain A, Thomas KJ, Usherwood T, et al. Validating the SF-36 health survey questionnaire: new outcome measure for primary care. BMJ. 1992;305:160\u20134.","journal-title":"BMJ"},{"key":"1410_CR22","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1097\/00005650-199206000-00002","volume":"30","author":"JE Ware Jr","year":"1992","unstructured":"Ware Jr JE, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992;30:473\u201383.","journal-title":"Med Care"},{"key":"1410_CR23","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1002\/1529-0131(200007)43:7<1478::AID-ANR10>3.0.CO;2-M","volume":"43","author":"M Kosinski","year":"2000","unstructured":"Kosinski M, Zhao SZ, Dedhiya S, Osterhaus JT, Ware Jr JE. Determining minimally important changes in generic and disease-specific health-related quality of life questionnaires in clinical trials of rheumatoid arthritis. Arthritis Rheum. 2000;43:1478\u201387.","journal-title":"Arthritis Rheum"},{"key":"1410_CR24","doi-asserted-by":"crossref","first-page":"121","DOI":"10.2165\/11531980-000000000-00000","volume":"70","author":"V Strand","year":"2010","unstructured":"Strand V, Singh JA. Newer biological agents in rheumatoid arthritis: impact on health-related quality of life and productivity. Drugs. 2010;70:121\u201345.","journal-title":"Drugs"},{"key":"1410_CR25","unstructured":"EuroQol Group. EQ-5D-5L User Guide. Version 2.1. 2015 [cited August 11, 2016]; Available from: https:\/\/euroqol.org\/wp-content\/uploads\/2016\/09\/EQ-5D-5L_UserGuide_2015.pdf . Accessed 5 Sept 2017."},{"key":"1410_CR26","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/0168-8510(96)00822-6","volume":"37","author":"R Brooks","year":"1996","unstructured":"Brooks R. EuroQol: the current state of play. Health Policy. 1996;37:53\u201372.","journal-title":"Health Policy"},{"key":"1410_CR27","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1007\/s11136-011-9903-x","volume":"20","author":"M Herdman","year":"2011","unstructured":"Herdman M, Gudex C, Lloyd A, Janssen M, Kind P, Parkin D, et al. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life Res. 2011;20:1727\u201336.","journal-title":"Qual Life Res"},{"key":"1410_CR28","doi-asserted-by":"crossref","first-page":"353","DOI":"10.2165\/00019053-199304050-00006","volume":"4","author":"MC Reilly","year":"1993","unstructured":"Reilly MC, Zbrozek AS, Dukes EM. The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics. 1993;4:353\u201365.","journal-title":"Pharmacoeconomics"},{"key":"1410_CR29","first-page":"236","volume":"67","author":"P Daul","year":"2009","unstructured":"Daul P, Grisanti J. Monitoring response to therapy in rheumatoid arthritis - perspectives from the clinic. Bull NYU Hosp Jt Dis. 2009;67:236\u201342.","journal-title":"Bull NYU Hosp Jt Dis"},{"key":"1410_CR30","doi-asserted-by":"crossref","first-page":"2272","DOI":"10.1002\/art.24638","volume":"60","author":"P Emery","year":"2009","unstructured":"Emery P, Fleischmann RM, Moreland LW, Hsia EC, Strusberg I, Durez P, et al. Golimumab, a human anti-tumor necrosis factor alpha monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: twenty-four-week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis. Arthritis Rheum. 2009;60:2272\u201383.","journal-title":"Arthritis Rheum"},{"key":"1410_CR31","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1136\/annrheumdis-2014-206106","volume":"74","author":"P Emery","year":"2015","unstructured":"Emery P, Burmester GR, Bykerk VP, Combe BG, Furst DE, Barre E, et al. Evaluating drug-free remission with abatacept in early rheumatoid arthritis: results from the phase 3b, multicentre, randomised, active-controlled AVERT study of 24\u00a0months, with a 12-month, double-blind treatment period. Ann Rheum Dis. 2015;74:19\u201326.","journal-title":"Ann Rheum Dis"},{"key":"1410_CR32","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1136\/annrheumdis-2015-207628","volume":"75","author":"GR Burmester","year":"2016","unstructured":"Burmester GR, Rigby WF, van Vollenhoven RF, Kay J, Rubbert-Roth A, Kelman A, et al. Tocilizumab in early progressive rheumatoid arthritis: FUNCTION, a randomised controlled trial. Ann Rheum Dis. 2016;75:1081\u201391.","journal-title":"Ann Rheum Dis"},{"key":"1410_CR33","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1136\/ard.2005.035709","volume":"65","author":"D Heijde van der","year":"2006","unstructured":"van der Heijde D, Klareskog L, Singh A, Tornero J, Melo-Gomes J, Codreanu C, et al. Patient reported outcomes in a trial of combination therapy with etanercept and methotrexate for rheumatoid arthritis: the TEMPO trial. Ann Rheum Dis. 2006;65:328\u201334.","journal-title":"Ann Rheum Dis"},{"key":"1410_CR34","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1136\/annrheumdis-2011-201247","volume":"72","author":"A Kavanaugh","year":"2013","unstructured":"Kavanaugh A, Fleischmann RM, Emery P, Kupper H, Redden L, Guerette B. Clinical, functional and radiographic consequences of achieving stable low disease activity and remission with adalimumab plus methotrexate or methotrexate alone in early rheumatoid arthritis: 26-week results from the randomised, controlled OPTIMA study. Ann Rheum Dis. 2013;72:64\u201371.","journal-title":"Ann Rheum Dis"},{"key":"1410_CR35","first-page":"1174","volume":"34","author":"JR Kirwan","year":"2007","unstructured":"Kirwan JR, Minnock P, Adebajo A, Bresnihan B, Choy E, de Wit M, et al. Patient perspective: fatigue as a recommended patient centered outcome measure in rheumatoid arthritis. J Rheumatol. 2007;34:1174\u20137.","journal-title":"J Rheumatol"},{"key":"1410_CR36","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1136\/annrheumdis-2014-eular.3168","volume":"73","author":"R Alten","year":"2014","unstructured":"Alten R, Strand V, Fleischmann R, Koncz T, Zwillich S, Bradley J, et al. Effects of tofacitinib monotherapy versus methotrexate on patient-reported outcomes in the 2-year phase 3 Oral Start trial in methotrexate-na\u00efve patients with rheumatoid arthritis [abstract]. Ann Rheum Dis. 2014;73:118\u20139.","journal-title":"Ann Rheum Dis"},{"key":"1410_CR37","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1056\/NEJMoa1507247","volume":"374","author":"MC Genovese","year":"2016","unstructured":"Genovese MC, Kremer J, Zamani O, Ludivico C, Krogulec M, Xie L, et al. Baricitinib in patients with refractory rheumatoid arthritis. N Engl J Med. 2016;374:1243\u201352.","journal-title":"N Engl J Med"}],"container-title":["Arthritis Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-017-1410-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T19:51:14Z","timestamp":1750881074000},"score":1,"resource":{"primary":{"URL":"http:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/s13075-017-1410-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9,18]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["1410"],"URL":"https:\/\/doi.org\/10.1186\/s13075-017-1410-1","relation":{},"ISSN":["1478-6362"],"issn-type":[{"value":"1478-6362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,9,18]]},"article-number":"208"}}